(LifeSiteNews) – One of the hypotheses suggesting that the COVID-19 pandemic may be a hoax, ruse, ploy, operational exercise, or something similar includes the supposition that the hoax is possibly being propagated by re-naming or re-branding a coronavirus or coronaviruses which were already circulating for many years before 2019. This hypothesis also supposes that such a coronavirus (or coronaviruses) effectively causes the common cold for most people.
There may be potentially significant information in the “Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019” which supports the above suppositions. As previous articles have mentioned, thorough discussions of supporting information can result in articles being lengthy. This article is instead going to provide basic information which may be explained more thoroughly in future articles.
The potentially significant information supporting the claim that COVID-19 may be a hoax propagated by falsely renaming circulating coronaviruses as “SARS-CoV-2” and/or renaming the common cold as “COVID-19” are amendments in the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. One amendment is partially provided as follows:
STRATEGIC INITIATIVES.—The Secretary [of the U.S. Department of Health and Human Services, acting through the Director of BARDA [Biomedical Advanced Research and Development Authority], may implement strategic initiatives […] to support innovative candidate products in preclinical and clinical development that address priority, naturally occurring and man-made threats that, as determined by the Secretary, pose a significant level of risk to national security based on the characteristics of a chemical, biological, radiological or nuclear threat, or existing capabilities to respond to such a threat (including medical response and treatment capabilities and manufacturing infrastructure). Such initiatives shall accelerate and support the advanced research, development, and procurement of countermeasures and products, as applicable, to address areas including—
“(i) chemical, biological, radiological, or nuclear threats, including emerging infectious diseases, for which insufficient approved, licensed, or authorized countermeasures exist, or for which such threat, or the result of an exposure to such threat, may become resistant to countermeasures or existing countermeasures may be rendered ineffective;
“(ii) threats that consistently exist or continually circulate and have a significant potential to become a pandemic, such as pandemic influenza, which may include the advanced research and development, manufacturing, and appropriate stockpiling of qualified pandemic or epidemic products, and products, technologies, or processes to support the advanced research and development of such countermeasures (including multiuse platform technologies for diagnostics, vaccines, and therapeutics; virus seeds; clinical trial lots; novel virus strains; and antigen and adjuvant material) [etc.] (133 STAT. 948, emphasis added)
The 2019 amendments, made only a few months before the reported outbreak of SARS-CoV-2 and COVID-19, discuss that the Secretary of the Department of Health and Human Services may implement “strategic initiatives” to “accelerate” the “advanced research, development, and procurement of countermeasures and products” to “address areas including” “emerging infectious diseases, for which insufficient approved, licensed, or authorized countermeasures exist” and “threats that consistently exist or continually circulate and have a significant potential to become a pandemic.” Coronaviruses would very likely be included in such a category.
And “strategic initiatives” may include national and international “exercises,” potentially including convening a full-scale response and recovery exercise. (Pages 9, 10, and 22; page 1; pages 3-4)
In other words, a potential “strategic initiative” used by the U.S. federal government to “accelerate” “advanced research and manufacturing infrastructure” and the “development” of products for “threats that consistently exist or continually circulate” would seemingly potentially include a falsified pandemic propagated by falsifying information using a continually or already circulating coronavirus. Without such a falsified pandemic initiative, such research, development, and “manufacturing infrastructure” may not have been “accelerated.”
RELATED: Congress made crucial change to vaccine definition weeks before COVID-19
And the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 makes another potentially significant amendment relevant to the above-mentioned amendment. The amendment below suggests the possibility of “prioritizing” “accelerating” “advanced research” for products for broadly labeled “at-risk individuals with relevant characteristics.” The 2019 amendment is at 133 STAT. 935 but is easier to understand with the complete wording of the U.S. federal law:
In carrying out the functions under this section, the Secretary may give priority to the advanced research and development of qualified countermeasures and qualified pandemic or epidemic products that are likely to be safe and effective with respect to children, pregnant women, older adults, and other at-risk individuals with relevant characteristics that warrant consideration during the process of researching and developing such countermeasures and products. (42 U.S.C. 247d–7e(c)(6), significant wording of 2019 amendment emphasized)
It is not clear what is meant by “other at-risk individuals with relevant characteristics that warrant consideration,” but it may be determinable. For example, those who are “at-risk” to viruses which typically cause the common cold are those with weakened immune systems, especially those with HIV/AIDS. Such persons may not have been included, at least not explicitly, in the pre-amendment definition of “at-risk individuals.”
The wording of the amendment may partially support the hypothesis that the U.S. federal government may have been attempting to lawfully authorize a hoax pandemic to be carried out by falsifying information about coronaviruses which mostly cause the common cold except for in “at-risk individuals with relevant characteristics that warrant consideration.” The broad wording may attempt to make sure to legally expand the U.S. federal health law definition of “at-risk individuals” for the section which describes “strategic initiatives” to “accelerate” research, development, and manufacturing for “threats that consistently exist or continually circulate and have a significant potential to become a pandemic” and/or “for which insufficient approved, licensed, or authorized countermeasures exist.” Prior to the reported COVID-19 pandemic, there was an influenza vaccine but no “approved, licensed, or authorized” coronavirus vaccine.
Prioritizing initiatives for “at-risk individuals with relevant characteristics that warrant consideration” may imply prioritizing initiatives for the common cold, which may include common cold causing coronaviruses for which countermeasures did not exist prior to what is reported to be COVID-19. Such initiatives may include falsifying a coronavirus pandemic as a full-scale national and international response and recovery exercise.
And there is still much more information to support such claims, but it will not be mentioned here.